DOCSLIB.ORG

In Vitro Screening of Psychoactive Drugs by [35S] Gtpγs Binding In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Vitro Screening of Psychoactive Drugs by [35S] Gtpγs Binding In 2328 Biol. Pharm. Bull. 30(12) 2328—2333 (2007) Vol. 30, No. 12 In Vitro Screening of Psychoactive Drugs by [35S]GTPgS Binding in Rat Brain Membranes ,a b a a Ryouichi NONAKA,* Fumiko NAGAI, Akio OGATA, and Kanako SATOH a Department of Environmental Health and Toxicology, Tokyo Metropolitan Institute of Public Health; 3–24–1 Hyakunincho, Shinjuku-ku, Tokyo 169–0073, Japan: and b Pharmaceutical Safety Guide section, Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government; 2–8–1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163–8001, Japan. Received June 26, 2007; accepted October 5, 2007; published online October 9, 2007 We constructed a reproducible, simple, and small-scale determination method of the psychoactive drugs -(that acted directly on the monoamine receptor by measuring the activation of [35S]guanosine-5؅-O-(3-thio triphosphate binding to guanine nucleotide-binding proteins (G proteins). This method can simultaneously measure the effects of three monoamines, namely dopamine (DA), serotonin (5-HT), and norepinephrine (NE), in rat brain membranes using a 96-well microplate. Activation of D1 and D2 receptors in striatal membranes by DA as well as 5-HT and NEa2 receptors in cortical membranes could be measured. Of 12 tested phenethylamines, 2,5-dimethoxy-4-chlorophenethylamine (2C-C), 2,5-dimethoxy-4-ethylphenethylamine (2C-E), and 2,5-dimethoxy- 4-iodophenethylamine (2C-I) stimulated G protein binding. The other phenethylamines did not affect G protein binding. All 7 tryptamines tested stimulated G protein binding with the following rank order of potency; 5- methoxy-N,N-dimethyltryptamine (5-MeO-DMT)Ͼ5-methoxy-N,N-diallyltryptamine (5-MeO-DALT)Ͼ5-methoxy- a-methyltryptamine (5-MeO-AMT)Ն5-methoxy-N,N-methylisopropyltryptamine (5-MeO-MIPT)Ͼ5-methoxy-N,N- diisopropyltryptamine (5-MeO-DIPT)ϾN,N-dipropyltryptamine (DPT)Նa-methyltryptamine (AMT). This assay system was able to designate psychoactive drugs as prohibited substances in accordance with criteria set forth by the Tokyo Metropolitan government. Key words G protein binding; monoamine; dopamine; serotonin; norepinephrine; psychoactive drug In today’s world including Japan, non-prescription psy- (for example, 3,4,5-trimethoxyamphetamine (TMA), 2,4,5- choactive drugs are widely used by many people, particularly trimethoxyamphetamine (TMA-2), and 2,4,6-trimethoxyam- by the young. These drugs have been synthesized by minor phetamine (TMA-6)) reveal no presynaptic effects, it is modifications to the chemical structures of existing drugs reported that these drugs elicit hallucinogenic effects in and are called designer drug. For example, methylene- human.5) Thus, it is also possible that these designer drugs dioxymethamphetamine (MDMA) was derived from amphet- could modify brain activity by directly interacting with amine by altering the natural molecular structure.1) Although monoamine receptors. Many monoamine receptors, includ- the use of MDMA is prohibited in many countries, new psy- ing DA, 5-HT, and NE receptors belong to the superfamily choactive chemicals are being constantly developed and can of seven-transmembrane-domain, guanine nucleotide-bind- be easily obtained from individuals or via the Internet. The ing protein (G protein)-coupled receptors.6) G protein-cou- Tokyo Metropolitan Government in Japan enacted an “Ordi- pled receptors play a crucial role in regulating physiological nance concerning the abuse prevention of the psychoactive functions, and consequently are targets for the action of drugs” in April 2006 that prohibited the manufacture, culti- many classes of drugs. Because the [35S]guanosine-5Ј-O-(3- vation, sales, possession, use, etc., of these drugs. Therefore, thio)-triphosphate ([35S]GTPgS) binding assay is thought to we are developing screening methods to rapidly elucidate the be a relatively simple functional assay of receptor-mediated effects of these drugs on the central nervous system. G protein activation,7) we tried to construct a simple and Psychoactive drugs are roughly classified into phenethyl- small-scale method for determining G protein binding using amine, tryptamine, and piperazine derivatives. Many of the the rat brain membranes. psychoactive drugs modify the monoamine neurotransmis- sion systems including the dopaminergic, serotonergic, and MATERIALS AND METHODS adrenergic neuronal systems.2,3) We previously constructed a reproducible, simple, and small-scale in vitro determination Chemicals Psychoactive chemicals were purchased from method for the reuptake and release of monoamines (dopamine adult goods shops in Tokyo (Table 1). The structures of the (DA), serotonin (5-HT), and norepinephrine (NE)) using rat drugs are shown in Fig. 1. The purity of the drugs was deter- brain membranes. This method was then applied to study the mined by HPLC (Alliance PDA system, Waters Co., MA, effects of designer drugs on monoamine reuptake and re- U.S.A.) with L-column ODS, 5 mm, 4.6ϫ150 mm (Chemi- lease. We have been investigating the effects of 21 designer cals Evaluation and Research Institute, Japan) and a solvent 8) drugs, some of which are known to be psychoactive in man. of H2O/acetonitrile/phosphoric acid/SDS (580/420/1/12.5 g). For example, 4-fluoroamphetamine (4-FMP), 1-(1,3-benzodi- Drugs were dissolved in dimethylsulfoxide (DMSO) for the oxol-5-yl)-2-butanamine (BDB), 2-methylamino-3,4-methyl- GTP binding assay. [35S]GTPgS (46.25 TBq/mmol) was enedioxy-propiophenone (methylone), and a-methyltrypta- purchased from Perkin Elmer Co., Ltd. (MO, U.S.A.). DA, 5- mine (AMT) showed strong reuptake inhibition and release HT, NE, guanosine 5Ј-diphosphate (GDP), 8-cyclopentyl- acceleration of DA, 5-HT, and NE.4) 1,3-dipropylxanthine (DPCPX), SCH23390, sulpiride, me- Although many of drugs described in our previous report4) thiothepin, WAY100635, SB224289, propranolol, and yohim- ∗ To whom correspondence should be addressed. e-mail: [email protected] © 2007 Pharmaceutical Society of Japan December 2007 2329 Table1. Psychoactive Drugs Characteristics No. Drugs Abbreviations Purity (%) Phenethylamines 1 3,4-Methylenedioxymethamphetamine MDMA 98.0 2 2-Methylamino-3,4-methylenedioxy-propiophenone Methylone 98.8 3 1-(1,3-Benzodioxol-5-yl)-2-butanamine BDB 97.1 4 N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine MBDB 99 5 2,5-Dimethoxy-4-chlorophenethylamine 2C-C 94.2 6 2,5-Dimethoxy-4-ethylphenethylamine 2C-E 100 7 2,5-Dimethoxy-4-iodophenethylamine 2C-I 99.1 8 3,4,5-Trimethoxyamphetamine TMA 99.3 9 2,4,5-Trimethoxyamphetamine TMA-2 98.6 10 2,4,6-Trimethoxyamphetamine TMA-6 98.1 11 2-Fluoroamphetamine 2FMP Ͼ98.0 12 3-Fluoroamphetamine 3FMP Ͼ98 13 4-Fluoroamphetamine 4FMP Ͼ98 Tryptamines 14 a-Methyltryptamine AMT 99.0 15 5-Methoxy-a-methyltryptamine 5-MeO-AMT 92.7 16 N,N-Dipropyltryptamine DPT 96.9 17 5-Methoxy-N,N-diisopropyltryptamine 5-MeO-DIPT 96.1 18 5-Methoxy-N,N-methylisopropyltryptamine 5-MeO-MIPT 99.5 19 5-Methoxy-N,N-dimethyltryptamine 5-MeO-DMT 91.7 20 5-Methoxy-N,N-diallyltryptamine 5-MeO-DALT 87.8 Piperazines 21 1-(3-Chlorophenyl)piperazine 3CPP 98.0 22 1-(4-Methoxyphenyl)piperazine 4MPP 90.0 23 1-Benzylpiperazine BZP 98.0 The purities were obtained by HPLC.8) Fig. 1. Structures of the Designer Drugs 2330 Vol. 30, No. 12 bine were obtained from Sigma-Aldrich (MO, U.S.A.). ing values for 0.1% DMSO from stimulated values (obtained Saponin was purchased from Calbiochem Co., Ltd. (La Jolla, in the presence of monoamines or drugs). The EC50 values U.S.A.). Other reagents used in the study were of the highest were calculated as the concentrations required to elicit G pro- grade commercially available. Lumasafe Plus, the scintilla- tein activation equal to half of the maximum effect. The % tion cocktail, was purchased from Lumac. Lsc B. V. (Gronin- Emax values represented the percent maximal increase in the gen, The Netherlands). binding above basal binding. The % of 5-HT maxima was Animals Male Sprague Dawley rats (Crl:CD(SD):300— determined by dividing NE- or drug-induced maximal bind- 400 g) were obtained from Charles River Japan (Kanagawa, ing by the 5-HT-stimulated maximal binding value which Japan) and were housed in a room at 22—24 °C, 45—65% was as a reference. humidity with 12 h-light and 12 h-dark cycles. Water and Statistical Analysis EC50 values were determined using food were supplied ad libitum. All procedures involving ani- the sigmoidal dose-response curve fitting function of Kalei- mals were approved by the institutional animal care and use daGraph ver. 4 software (Synergy Software, PA, U.S.A.). The committee and conform to the guidelines in The UFAW data represented the mean values of three independent exper- Handbook on the Care and Management of Laboratory Ani- iments (nϭ3). mals. Membrane Preparation Male SD rats were killed by RESULTS decapitation under ether anesthesia and their brains were quickly removed. Membranes were prepared according to Pharmacological Properties of [35S]GTPgS Binding methods reported by Breivogel et al..9) The cerebral cortex of Brain Membranes Drug-stimulated G protein binding and striatum were dissected on ice and homogenized in 25 was successfully determined using the saponin-treated brain volumes of ice-cold HEPES buffer (pH 7.6, 20 mM HEPES, membranes (data not shown). We optimized the sensitivity of 7mM MgCl2, 100 mM NaCl, 1 mM EDTA, 0.2 mM dithiothre- the assay system for screening the GTP-binding assay in- itol (DTT)) by 20 strokes with a Teflon-glass homogenizer. duced by DA, 5-HT, and NE. The optimal assay conditions All subsequent centrifuge procedures were carried out at (reaction time and temperature, DPCPX content in the reac- 4°C. Following centrifugation of the homogenate at 800ϫg tion mixture, protein concentration of brain membranes; data for 10 min, the supernatant was homogenized with a Polytron not shown) are described in the Materials and Methods.
Load more

Recommended publications
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
    [Show full text]
  • A General Approach to the Screening and Confirmation of Tryptamines And
    Available online at www.sciencedirect.com Talanta 74 (2008) 512–517 A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation Bo-Hong Chen a, Ju-Tsung Liu b, Wen-Xiong Chen a, Hung-Ming Chen a, Cheng-Huang Lin a,∗ a Department of Chemistry, National Taiwan Normal University, 88 Sec. 4, Tingchow Road, Taipei, Taiwan b Forensic Science Center, Military Police Command, Department of Defense, Taipei, Taiwan Received 6 March 2007; received in revised form 12 June 2007; accepted 13 June 2007 Available online 19 June 2007 Abstract Certain characteristic fragmentations of tryptamines (indoleethylamine) and phenethylamines are described. Based on the GC–EI/MS, LC–ESI/ MS and MALDI/TOFMS, the mass fragmentations of 13 standard compounds, including ␣-methyltryptamine (AMT), N,N-dimethyltryptamine (DMT), 5-methoxy-␣-methyltryptamine (5-MeO-AMT), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-dibutyltryptamine (DBT), N,N-diisopropyltryptamine (DIPT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-methoxy-N,N-diisopropyltryptamine (5-MeO- DIPT), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (3,4-MDA), 3,4-methylenedioxymethamphetamine (3,4-MDMA) and 2- methylamino-1-(3,4-methylenedioxyphenyl)butane (MBDB), were compared. As a result, the parent ions of these analytes were hard to be obtained by GC/MS whereas the protonated molecular ions can be observed clearly by means of ESI/MS and MALDI/TOFMS. Furthermore, two major + + + + characteristic fragmentations, namely and ␣-cleavage ([M +H] → [3-vinylindole] ) and ␤-cleavage ([M +H] → [CH2N RN1RN2]), are produced when the ESI and MALDI modes are used, respectively. In the case of ESI/MS, the fragment obtained from ␣-cleavage is the major process.
    [Show full text]
  • An Analysis of the Synthetic Tryptamines AMT and 5-Meo-DALT: Emerging “Novel Psychoactive Drugs”
    Accepted Manuscript An Analysis of the Synthetic Tryptamines AMT and 5-MeO-DALT: Emerging “Novel Psychoactive Drugs” Warunya Arunotayanun, Jeffrey W. Dalley, Xi-Ping Huang, Vincent Setola, Ric Treble, Leslie Iversen, Bryan L. Roth, Simon Gibbons PII: S0960-894X(13)00394-6 DOI: http://dx.doi.org/10.1016/j.bmcl.2013.03.066 Reference: BMCL 20302 To appear in: Bioorganic & Medicinal Chemistry Letters Received Date: 31 January 2013 Revised Date: 18 March 2013 Accepted Date: 20 March 2013 Please cite this article as: Arunotayanun, W., Dalley, J.W., Huang, X-P., Setola, V., Treble, R., Iversen, L., Roth, B.L., Gibbons, S., An Analysis of the Synthetic Tryptamines AMT and 5-MeO-DALT: Emerging “Novel Psychoactive Drugs”, Bioorganic & Medicinal Chemistry Letters (2013), doi: http://dx.doi.org/10.1016/j.bmcl. 2013.03.066 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Graphical Abstract To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered. An Analysis of the Synthetic Tryptamines AMT and 5- Leave this area blank for abstract info. MeO-DALT: Emerging “Novel Psychoactive Drugs” Warunya Arunotayanun, Jeffrey W.
    [Show full text]
  • M a P S • V O L U M E X I I I N U M B E R 2
    m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 1 2 m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 Divine Spark The cover of this MAPS bulletin is an image from visionary artist Alex Grey’s triptych Holy Fire, which was inspired by one of Alex’s early MDMA experiences. We thought it was an appropriate choice to ex- press our emotions at obtaining Institutional Review Board (IRB) approval for Dr. Mithoefer's MAPS-sponsored MDMA/PTSD study (see page 7). The rest of the images on this page and on the back cover are from the 2003 Burning Man Festival, at which MAPS provided psychedelic emergency services. (Article on page 28). In the photo above, members of the Fire Conclave open the festivities at the Burning of the Man, the climax of the week-long festival. The photo below depicts the more somber burning of the Temple of Honor, at which Burning Man participants remember loved ones by leaving notes and tokens inside. As the temple burned, MAPS president Rick Doblin threw in the fire the original copies of the last set of documents about protocol design issues exchanged between MAPS and the IRB. This symbolized his hopes that we would finally move beyond the paperwork of the approval process to the therapeutic work of the study itself.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Update of the Generic Definition for Tryptamines
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Zahi Sulaiman 2nd Floor (NW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Norman Baker MP, Minister for Crime Prevention Home Office 2 Marsham Street London SW1P 4DF 10 June 2014 Dear Minister, In December 2013, you commissioned the ACMD to begin a regular review of generic definitions under the Misuse of Drugs Act 1971, with the aim of capturing emerging new psychoactive substances. These drugs are variants of controlled drugs and fall outside the existing scope of the Misuse of Drugs Act 1971. The ACMD has considered evidence available on tryptamines in the context of the Misuse of Drugs Act 1971 and I enclose the Advisory Council’s advice and an expanded definition for tryptamine compounds with this letter. The ACMD’s NPS Committee has firstly reviewed previous research and existing controls to identify those tryptamines now seen to evade the existing controls. The ACMD has also reviewed data provided by the Home Office’s early warning systems and networks, clinical toxicology, prevalence and neuropharmacology in arriving at the expanded generic definition. This expanded generic definition will bring drugs such as alpha-methyltryptamine (AMT) as well as 5-MeO-DALT within the scope of the Misuse of Drugs Act 1971. These are highly potent hallucinogens which act on the 5HT2A receptor, in the same way as LSD. The ACMD therefore recommends that the tryptamines covered by the proposed expanded generic definition in this report, are controlled under the Misuse of Drugs Act (1971) as Class A substances.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Test Purchase of New Synthetic Tryptamines Via the Internet: Identity Check by GC-MS and Separation by HPLC
    Journal of Applied Pharmaceutical Science Vol. 6 (01), pp. 028-034, January, 2016 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2016.600105 ISSN 2231-3354 Test purchase of new synthetic tryptamines via the Internet: Identity check by GC-MS and separation by HPLC Magdalena Taschwer, Edith Ebner, Martin G Schmid* Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Universitätsplatz 1, A-8010 Graz, Austria. ABSTRACT ARTICLE INFO Article history: Over the past few years, a continuous alteration of the recreational drug market took place. Among other novel Received on: 25/09/2015 psychoactive drugs, new synthetic tryptamine derivatives appeared on the market. These compounds are mainly Revised on: 18/10/2015 traded via the Internet, which has become an important marketplace for the sale of recreational drugs. The goal of Accepted on: 08/11/2015 our research was to check, if 13 new synthetic tryptamines obtained by test purchase via different online vendors Available online: 26/01/2016 meet the promised identity. Analysis was performed by GC-MS, using a common 30 m HP-5MS capillary column as stationary phase. Subsequently, a simple HPLC method for the separation of these tryptamines was Key words: developed. Therefore, the aim was to establish a method to separate a broad spectrum of trypamines Tryptamines, Legal highs, simultaneously within short time. Measurements were performed by a LiChrospher® RP-18e column and a Novel psychoactive drugs, mobile phase consisting of 0.1% triethylammonium acetate buffer, methanol and acetonitrile. Both presented HPLC, GC-MS. methods were found to be suitable for the identification as well as separation of tryptamines as the analysis times were short and the selectivity sufficient.
    [Show full text]
  • Newer Unregulated Drugs Look-Up Table
    Newer Unregulated Drugs Look-up Table List Name Chemical Name/AKA Type of drug Notes Stimulant Regulation under MDA (Sch. 1 or TCDO) Stimulant/Hallucinogen Regulation under MDA (Sch. 2-5) Hallucinogen Regulated by PSA Depressant Exempt Cannabinoid Uncertain/requires clarification 1P-LSD 1-propionyl-lysergic acid diethylamide Hallucinogen An LSD analogue that side-stepped MDA and was on sale as an NPS; now covered by the PSA. 2-AI 2-Aminoindane Stimulant, amphetamine analogue Reported in the UK in 2011 by the Forensic Early 2-MAI N-methyl-2-Aminoindane Warning System (FEWS). Had been on sale via number MMAI of online stores; covered by PSA. 2-MeO-ketamine Methoxyketamine Related to methoxetamine so a relative Believed to have been made a CD at the same time as Methoxieticyclidine of ketamine – i.e. a dissassociative Methoxetamine anaesthetic hallucinogen 2C-B-BZP (1-(4-bromo-2,5- Piperazine family; stimulant Class B dimethoxybenzyl)piperazine) 2-DPMP Desoxypipadrol stimulant Strong and long acting stimulant; reported duration of 2-diphenylmethylpiperidine effect 24-28hrs or more and effective at very low doses. Had been on sale in the UK and cropped up in branded “Ivory Wave” and in other compounds. Linked to fatalities. Class B, Sch1. 2-NE1 APICA Synthetic cannabinoid receptor agonist 3rd generation SCRA. Covered by PSA SDB-001 N-(1-adamantyl)-1-pentyl-1H-indole-3- carboxamide 3-FPM Phenzacaine Stimulant, euphoriants Sibling of the controlled drug Phenmetrazine. Emerged PAL-593 2015. Covered by PSA 2-(3-fluorophenyl)-3-methylmorpholine 3-hydroxyphenazepam Benzo, GABA-nergic PSA 3-MeO-PCE (3-methoxyeticyclidine) Related to methoxetamine so a relative Probably regulated under the same clause that made of ketamine – i.e.
    [Show full text]
  • Amphetamine-Related Drugs Neurotoxicity in Humans and In
    Abbreviations and chemical names of compounds not defined in the text [3H]CP-55: 940, 5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; 18F-DOPA: 18F-fluoro-L-dihydroxyphenylalanine; 25C-NBOME: 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2 methoxyphenyl)methyl]ethanamine; 25I-NBOME: 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine; 2C-B: 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine; 4-HO-DALT: 3-{2-[di(prop-2-en-1-yl)amino]ethyl}-1H-indol-4-ol; 5F-ADBINACA: (1-(5-fluoro-pentyl)-1H-indole-3-carboxylic acid (1-carbamoyl-2-methyl-propyl)-amide; 5F-AKB-48: N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; 5F-PB-22: 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester; 5F-SDB-005: 1-(5-Fluoropentyl)-N-phenyl-1H-indole-3-carboxamide; 5-MeO-AMT: 5-methoxy-α-methyltryptamine; 5-MeO-DALT: N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1- amine; AB-FUBINACA: N‐(1‐amino‐3‐methyl‐1‐oxobutan‐2‐yl)‐1‐(4‐fluorobenzyl)‐1H–indazole‐3‐carboxamide; AB-PINACA: (S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-inda-zole-3-carboxamide; ADB-FUBINACA: (S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluoroben-zyl)-1H-indazole-3-carboxamide; AKB-48: N-(1-Adamantyl)-1-pentylindazole-3-carboxamide; AM 251: N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; AMB-FUBINACA: methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; AMT: α-methyltryptamine; BB-22: 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester; Bromo-DragonFly: 1-(4-Bromofuro[2,3-f]
    [Show full text]